Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 407


Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.

Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K.

J Immunol. 2004 Feb 15;172(4):2232-7.


Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.

Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P.

J Immunol. 1999 Sep 1;163(5):2928-36.


Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.

So T, Hanagiri T, Chapiro J, Colau D, Brasseur F, Yasumoto K, Boon T, Coulie PG.

Cancer Immunol Immunother. 2007 Feb;56(2):259-69. Epub 2006 Jun 7.


Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.

Carrasco J, Van Pel A, Neyns B, Lethé B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K, Boon T, Godelaine D.

J Immunol. 2008 Mar 1;180(5):3585-93.


Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.

Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, Van Pel A.

J Immunol. 1999 Jun 1;162(11):6849-54.


Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.

Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P, Schuler G.

J Immunol. 2004 Jan 15;172(2):1304-10.


A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors.

Sun Z, Lethé B, Zhang Y, Russo V, Colau D, Stroobant V, Boon T, van der Bruggen P.

Cancer Immunol Immunother. 2006 Jun;55(6):644-52. Epub 2005 Sep 27.


A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.

Zhang Y, Chaux P, Stroobant V, Eggermont AM, Corthals J, Maillère B, Thielemans K, Marchand M, Boon T, Van Der Bruggen P.

J Immunol. 2003 Jul 1;171(1):219-25.


The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses.

Sartorius R, Pisu P, D'Apice L, Pizzella L, Romano C, Cortese G, Giorgini A, Santoni A, Velotti F, De Berardinis P.

J Immunol. 2008 Mar 15;180(6):3719-28.


A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T.

Eur J Immunol. 1994 Dec;24(12):3038-43.


Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.

Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A.

J Immunol. 2003 Nov 1;171(9):4893-7.


A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.

Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P.

Eur J Immunol. 1999 Oct;29(10):3329-37.


A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules.

Luiten RM, Demotte N, Tine J, van der Bruggen P.

Tissue Antigens. 2000 Jul;56(1):77-81.


A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.

Godelaine D, Carrasco J, Brasseur F, Neyns B, Thielemans K, Boon T, Van Pel A.

Cancer Immunol Immunother. 2007 Jun;56(6):753-9. Epub 2006 Nov 10.


A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells.

Ottaviani S, Colau D, van der Bruggen P, van der Bruggen P.

Cancer Immunol Immunother. 2006 Jul;55(7):867-72. Epub 2005 Sep 3.


Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.

Corbière V, Nicolay H, Russo V, Stroobant V, Brichard V, Boon T, van der Bruggen P.

Tissue Antigens. 2004 May;63(5):453-7.


The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.

zum Büschenfelde CM, Metzger J, Hermann C, Nicklisch N, Peschel C, Bernhard H.

J Immunol. 2001 Aug 1;167(3):1712-9.


A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes.

Schultz ES, Zhang Y, Knowles R, Tine J, Traversari C, Boon T, van der Bruggen P.

Tissue Antigens. 2001 Feb;57(2):103-9.


Supplemental Content

Support Center